In The News

Glycemic Control and Hypoglycemia With New Insulin Glargine 300 U/mL vs Glargine 100 U/mL in Patients With Type 2 Diabetes Using Basal Insulin and Oral Antihyperglycemic Drugs

This randomized, multicenter, open-label, two-arm study compared the efficacy of insulin glargine 300 U/mL (Gla-300) vs 100 U/mL (Gla-100) in patients with type 2 diabetes treated with basal insulin and oral antihyperglycemic drugs (excluding sulfonylureas). The study (EDITION 2) was conducted over 12 months. Both Gla-300 and Gla-100 were associated with A1C reductions from baseline (-0.55% vs -0.50%, respectively).

Combination of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin With Insulin-Based Regimens in Type 2 Diabetes and Chronic Kidney Disease

Since limited glucose-lowering treatment options are available for type 2 diabetes (T2D) patients with chronic kidney disease (CKD), this study evaluated the safety and efficacy of linagliptin plus insulin in patients with T2D and mild-to-severe renal impairment. Participant data were obtained from 2 phase 3 trials (N=811). After 24 weeks, mean placebo-adjusted A1C reductions from baseline of −0.59% were observed in patients with mild renal impairment and −0.69% in patients with moderate renal impairment.

A Randomized, Controlled Trial of Liraglutide 3.0 mg in Weight Management

This 56-week, double-blind trial included 3731 patients with a body mass index (BMI) of at least 30 kg/m2 (or 27 kg/m2 in individuals with treated or untreated dyslipidemia or hypertension) who did not have type 2 diabetes. Patients were randomly assigned in a 2:1 ratio to receive lifestyle modification counseling plus a once-daily injection of liraglutide 3.0 mg or placebo. The primary endpoints were change in body weight and the proportion of patients losing at least 5% and more than 10% of their initial body weight.

An Observational Study of Patient Characteristics and Mortality Following Hypoglycemia in the Community

This study identified patient characteristics and mortality rates associated with severe hypoglycemic events requiring emergency services intervention. Data (2005-2013) were obtained as part of emergency services calls for hypoglycemia treatment in a UK community with 34,000 residents with diabetes. Investigators identified 1835 hypoglycemic events among 1156 patients, 44% with type 2 diabetes (T2D) and 45% with type 1 diabetes (T1D). Investigators found that patients with severe hypoglycemia and T1D were more likely to be male.

Early Specialist Care for Diabetes: Who Benefits Most?

This propensity score-matched cohort study examined whether early endocrinologist care reduces the risk of cardiovascular (CV) complications in patients with newly diagnosed diabetes. Patient health data were obtained from Ontario, Canada, provincial records, and patients who were referred to endocrinologist care within 1 year of diagnosis were matched with patients who received primary care alone. Data on patients’ chronic conditions were used to assign a medical complexity score, and outcomes were tracked for 3 to 5 years.

Leading Medical Association Announces Scientific and Clinical Review of Potential Relationship Between Diabetes Ketoacidosis and SGLT2 Inhibitors

The American Association of Clinical Endocrinologists (AACE), the leading medical organization representing more than 6000 experts in the care and treatment of diabetes patients, today announced plans to convene a conference of US and international experts to examine the issue of diabetic ketoacidosis (DKA) among patients treated with SGLT2 inhibitors, a class of medications approved for use in adults with type 2 diabetes. AACE will conduct this meeting to provide answers to questions from its membership raised in response to recent case reports and publications on the subject.

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes

This 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension was developed to assess the efficacy and safety of the selective sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin 10 mg vs placebo in patients with type 2 diabetes, preexisting cardiovascular disease, and a history of hypertension. Co-primary endpoints were A1C reduction from baseline and the proportion of patients achieving a combined endpoint involving reductions in the following parameters: A1C ≥0.5%, body weight ≥3%, and systolic blood pressure ≥3 mm Hg.

New Position Statement: Diabetes Self-management Education and Support in Type 2 Diabetes

The American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics have released a joint position statement on diabetes self-management education and support (DSME/S) for patients with type 2 diabetes. The statement provides an algorithm to guide providers on when to refer patients for education and support, and highlights 4 critical times for assessing the need for DSME/S: at patient diagnosis; annually; when new disease complications affect disease management; and, when transitions in care occur.

Biomarkers Related to Severe Hypoglycemia and Lack of Good Glycemic Control in ACCORD

Biomarkers Related to Severe Hypoglycemia and Lack of Good Glycemic Control in ACCORDJune 2015. This study was developed to identify blood biomarkers that predict the success of glycemic control intensification in patients with type 2 diabetes. Investigators used a nested, case-control design to compare case (n=326) and control (n=1075) patients using data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study.

Veterans Affairs Diabetes Trial: Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes

Previously, the 5.6-year Veterans Affairs Diabetes Trial (VADT) found that intensive glucose lowering did not significantly reduce the rate of major cardiovascular (CV) events compared with standard therapy in patients with type 2 diabetes (T2D). This publication reports on the extended follow-up of VADT participants over a median of 9.8 years, with data available for 92.4% of patients. The primary outcome was time to the first major CV event; secondary outcomes were CV mortality and all-cause mortality.